Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Patients With Nonalcoholic Fatty Liver Disease: a Single Center, Double-blind, Randomized, Placebo-Controlled, Phase 2a Trial
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Colestyramine (Primary) ; Elobixibat (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 15 Nov 2021 Status changed from active, no longer recruiting to completed.
- 13 Apr 2021 Planned End Date changed from 30 Jun 2021 to 15 Oct 2021.
- 13 Apr 2021 Planned primary completion date changed from 30 Apr 2021 to 30 Jul 2021.